牛牛AI助理已提取核心訊息
On December 31, 2023, Tang Capital Partners, LP, along with Tang Capital Management, LLC, and Kevin Tang, collectively reported a change in their holdings of bluebird bio, Inc. According to the Schedule 13G/A filing with the Securities and Exchange Commission, the group beneficially owns 1,700,000 shares of bluebird bio's common stock, which represents 0.9% of the company's class of securities. The filing indicates that as of the date of the filing, the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities. The shares are reported to be held with shared voting and dispositive power among the three reporting entities. The filing, dated February 14, 2024, also includes a certification stating that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
On December 31, 2023, Tang Capital Partners, LP, along with Tang Capital Management, LLC, and Kevin Tang, collectively reported a change in their holdings of bluebird bio, Inc. According to the Schedule 13G/A filing with the Securities and Exchange Commission, the group beneficially owns 1,700,000 shares of bluebird bio's common stock, which represents 0.9% of the company's class of securities. The filing indicates that as of the date of the filing, the reporting persons have ceased to be the beneficial owner of more than five percent of the class of securities. The shares are reported to be held with shared voting and dispositive power among the three reporting entities. The filing, dated February 14, 2024, also includes a certification stating that the shares were not acquired for the purpose of changing or influencing the control of the issuer.
2023年12月31日，唐資本合夥人有限責任公司以及唐資本管理有限責任公司和唐凱文共同報告了其持有的藍鳥生物公司的變動。根據向美國證券交易委員會提交的附表13G/A文件，該集團實益擁有藍鳥生物1700,000股普通股，佔該公司證券類別的0.9％。該文件表明，截至申報之日，申報人已不再是該類別超過5％的證券的受益所有人。據報道，這三個申報實體以共同的投票權和處置權持有這些股份。該文件日期爲2024年2月14日，其中還包括一份證明，表明收購這些股票的目的不是爲了改變或影響發行人的控制權。
2023年12月31日，唐資本合夥人有限責任公司以及唐資本管理有限責任公司和唐凱文共同報告了其持有的藍鳥生物公司的變動。根據向美國證券交易委員會提交的附表13G/A文件，該集團實益擁有藍鳥生物1700,000股普通股，佔該公司證券類別的0.9％。該文件表明，截至申報之日，申報人已不再是該類別超過5％的證券的受益所有人。據報道，這三個申報實體以共同的投票權和處置權持有這些股份。該文件日期爲2024年2月14日，其中還包括一份證明，表明收購這些股票的目的不是爲了改變或影響發行人的控制權。
有用
沒用